Please typ	e a plus sig	gn (+) insi	ide tris b	0 \ P + JUL 0 9	2002			·		/SB/08A (08-00)
Cube	· · · · · · · · · · · · · · · · · · ·	1440	, mTO	E.	10			Complete if Known	유	7
Suos	stitute for fo	OTTI 1449.	APIU	BTRAD	EMAIN	Applie	ation Number	10/004,118		<u>- M</u>
IN	FORM	ATION	N DISC	CLOSUR		Filing I		October 30, 2001	Z	80
				PLICAN			amed Inventor	Moran	<u> </u>	F 511
					1	Group A		1644	- 3	C -
	(use as n	any she	ets as n	ecessary)			er Name			21
Sheet	1	C	of 6	5		Attorne	y Docket Number	BMED-004/01US	- <del>6</del>	ê m
								<u></u>	<u> </u>	
						U.S. PA	TENT DOCUMENT	rs	2900	
	T	T					<del> </del>			
			U.S	S. Patent Doc	ument				1	
Examiner	Cite		Number	ſ	Kind C	ode <sup>2</sup>	Name of Patentee	or Applicant of Cited Documer	nt I	lication of Cited  MM-DD-YYYY
Initials*	No.1				(if kno	wn)			Document is	11VI-DD-1.1.1
Uh	P1	6,172	2.046				J. K. Albrecht		01-09-200	11
7/10-		1-	,				0.11.11		01-07-200	-
	-	<u> </u>						· · · · · · · · · · · · · · · · · · ·	_	
	<del>                                     </del>	+			<del> </del>		<del></del>			
	+	<del>                                     </del>								
	+	-			-					
		<del> </del>								
	+	ļ			<b></b>			·		
		1								
	<del> </del>	<del>-</del>								
		<u> </u>								
		1	*							
					FC	REIGN	PATENT DOCUME	ENTS		
<del></del>	T ov.	1								
Examiner Initials*	Cite No. <sup>1</sup>		Forei	gn Patent Do	cument	,	N 6 D		Date of Publicat	tion
linuais	140.	Office <sup>3</sup>	3	Number <sup>4</sup>	Kin	d Code <sup>5</sup>		itee or Applicant of Cited Document	of Cited Docum	nent T6
		Onice		Number		known)	·	Document	MM-DD-YYYY	Y .
					Ť					<del></del>
					$\longrightarrow$				<u> </u>	
	+	+			$\rightarrow$					
		ļ ———			<del></del>					

Examiner /////	Date
Signature // //	Considered 6-11-03
*EXAMINER: Initial if reference considered, whether or not of	sitation is in conformance with MPEP 609. Draw line through citation if not in conformance

TEXAMINER: Invital if reference considered, whether or not citation is in conformance with MPEP and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 See attached Kinds of U.S. Patent Documents.
 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
 Applicant is to place a check mark here if English language Translation is attached.

Please typ	oe a plus sign (+) i	nside ta	S box → ⊕ P €  JUL 0 9 200	56147		P.TO/SB	3/08A ((	08-00)
Sub	stitute for form 14	49A/PT			Complete if Known	呈	,	뀨
			TRANSMA	Application Number Filing Date	10/004,118	m)		111
IN	FORMATIC	DN DI	SCLOSURE	Filing Date	October 30, 2001	Z	Ŭ.	()
ST	CATEMENT	BY A	PPLICANT	First Named Inventor	Moran	mi	دستز	577
	,			Group Art Unit	1644		9	
	(use as many s	neets a.	s necessary)	Examiner Name		6	2	
Sheet	2	of	6	Attorney Docket Number	BMED-004/01US	90/	02	
						12		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
All	D1	ADOLF GR et al., Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochimica et Biophysica Acta 1991;1089:167-174	
V	D2	ADOLF GR et al., Purification and characterization of natural human interferon ω1. J. Biol. Chem. 1990;265:9290-5	
·	D3	ADOLF GR., Antigenic structure of human interferon ω1 (Interferon αII1): comparison with other human interferons, J. Gen. Virol. 1987;68:1669-1676	
	D4	ADOLF GR., Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN, Virology 1990;175:410-71	
	D5	AULITZKY WE, Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and Interleukin 2, Ann. Hematol. 1991; 62: 25-31.	
	D6	BALKWILL FR, Interferons. In: Cytokines in cancer therapy, Oxford University Press, 1989.	
	D7	BALKWILL, FR, Interferons, Lancet 1989; 13: 1060-1063.	
	D8	BEKKERING FC, et al., Estimation of Early Hepatitis C Viral Clearance in Patients Receiving Daily Interferon and Ribavirin Therapy Using a Mathematical Model, Hepatology 2001;33:419-23	
	D9	BOLINGER AM et al., Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders, Clin Pharm 1992 Oct;11(10):834-50	
	D10	BONKOVSKY HL et al., Outcomes research in chronic viral hepatitis C: effects of interferon therapy, In Process Citation Can J Gastroenterol 2000 Jul-Aug;14 Suppl B:21B-29B	
	D11	BORDEN EC et al., Second-generation interferons for cancer: clinical targets In Process Citation, Semin Cancer Biol 2000 Apr; 10(2):125-44	
	D12	CONDINO-NETO A; Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferonresponsive variant of chronic granulomatous disease due to a splice site consensus region mutation, Newburger PE Blood 2000 Jun 1;95(11):3548-54	

		D13	DAVIS G, et al., Durability of viral response to interferon alone or in	Γ	
		0.5	combination with oral ribavirin in patients with chronic hepatitis C. Program and		
			shetracts of the 50th Annual Meeting and Postgraduate Courses of the American	一	
11			abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases November 5-9, 1999; Dallas, Texas.	兰	
1/l	L			C.	月
<del>'//</del>		514	Abstract 570.  JUL 0 9 2002  DI MARCO V et al. Compliand treatment of release of changing herestitis Cavith		- 日
+U		D14	DI MARCO V, et al., Combined treatment of relapse of chronic hepatitis C with high-dose alpha-2B interferozolus ribasium for 6 or 12 months. Program and		er er
	7		I man door dipid 22 miletrorogyplus righterm for o or 12 mondie. Trogram und		
1			abstracts of the 50th Annual Meeting and Postgraduate Courses of the American	Š	7nn2
			Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas.	600/2900	'`]
	1.		Abstract 569.	8	_
		D15	ELIAS L et al., Infusional interleukin-2 and 5-fluorouracil with subcutaneous		
			interferon-alpha for the treatment of patients with advanced renal cell carcinoma:		
	$\perp$		a southwest oncology group Phase II study. Cancer 2000 Aug 1;89(3):597-603		
		D16	FANG JW S, et al., The impact of baseline liver histology on virologic response		
			to interferon alpha-2b± rho ribavirin therapy in patients with chronic hepatitis C.		
			Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of		
			the American Association for the Study of Liver Diseases; November 5-9, 1999;		
L			Dallas, Texas. Abstract 572.		
		D17	FERENCI P, et al., Combination of interferon (IFN) induction therapy and		$\neg$
l.			ribavirin in chronic hepatitis C. Program and abstracts of Digestive Disease		
			Week 2000; May 21-24, 2000; San Diego, California. Abstract 977.		
		D18	FONTAINE H et al.; Recovery from chronic hepatitis C in long-term responders		
	1		to ribavirin plus interferon alfa letter Pol S: Lancet 2000 Jul 1;356(9223):41		
		D19	GLUE P, et al., A dose-ranging study of Peg-intron and ribavirin in chronic		
	1		hepatitis C – safety, efficacy, and virological rationale. Program and abstracts of		
			the 50th Annual Meeting and Postgraduate Courses of the American Association		
			for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract		
			571.		
1		D20	GONZALES HJ, et al., Randomized controlled trial including an initial 4-week		
			"induction" period during one year of high-dose interferon alfa-2B treatment for		
			chronic hepatitis C. Program and abstracts of Digestive Disease Week 2000;		
			May 21-24, 2000; San Diego, California. Abstract 975.		
		D21	GRANT PR et al., Combination therapy with interferon-alpha plus N-acetyl		
			cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre		
	,		study. J Med Virol 2000 Aug;61(4):439-42		
		D22	HEIM MH, Intracellular signaling and antiviral effects of interferons. Dig Liver		
			Dis 2000 Apr;32(3):257-63		
			TABLE COMP. LAND. AT		
		D23	HELLSTRAND K et al., Histamine and the response to IFN-alpha in chronic		
4			hepatitis C. Interferon Cytokine Res 1998 Jan; 18(1):21-2		
		D24	HELLSTRAND K et al., Histamine and cytokine therapy Acta Oncol	<del> </del>	$\dashv$
		D27	1998;37(4):347-53		1
			1220,01(1).01/10	L	
		D25	HELLSTRAND K et al., Histamine in immunotherapy of advanced melanoma: a		$\neg$
			pilot study. Cancer Immunol Immunother 1994 Dec. 39(6):416-9	1	
<u> </u>				ļ	
1		D26	ISAACS A, et al., Virus interference. I. The interferon. Pro. R. Soc. Lond. B.		
"	$U \mid$		Biol. Sci. 1957; 147: 258-267		
				i	

		D27	KHALILI M et al., Interferon and ribavirin versus interferon and amantadine in	
	1		interferon nonresponders with chronic hepatitis C see comments Am J	
	1/1		Gastroenterol 2000 May;95(5):1284-9	
	////	D28	KITA Y et al., Characterization of a polyethylene glycol conjugate of	
		D28	recombinant human interferon-gamma. Drug Des Deliv 1990 Sep;6(3):157-67	-
	A D		Tecombinant numan interferon-gamma. Drug Des Denv 1990 Sep,0(3):137-0/83	
	01.6	2	KNOBLER RL et al., Systemic alpha-interferon therapy of multiple sclerosis.	
/		183	Neurology 1984; 34: 1273-1279	
	1 2 200	2	remotogy 1764, 54. 1275-1277	<b>1</b> 1
		DE	KOVACEVIC Z et al., Treatment of chronic viral hepatitis B in secondary	2
		105	membranoproliferative glomerulonephritis using recombinant alfa-2 interferon	2002
/	E		Maksic Dj Vojnosanit Pregl 2000 Mar-Apr;57(2):235-40	~ 1
<i>(</i> 6)	72	D31	KRACKE A, et al., Mx proteins in blood leukocytes for monitoring interferom	
/	2002	بر ال	beta-1b therapy in patients with MS. Neurology 2000;54:193-9	
	0 3 5005		beta-10 dierapy in padents with Mis. Neurology 2000,54.175-7	
/ 30		F/D32	KRONENBERGER B, et al., Influence if interferon-alpha on CD82-expression in	
PIN	T& TRADEMA	7	HCV-positive patients. Program and abstracts of Digestive Disease Week 2000;	4
"	A TRAU		May 21-24, 2000; San Diego, California. Abstract 976.	
		D33	KROWN SE; Interferons and interferon inducers in cancer treatment. Seminars	<b></b>
		ا دورر	in Oncology 13(2): 207-217, 1986.	
			111 O1100105y 13(2). 201-211, 1700.	
		D34	KUNZI MS, et al., Role of interferon-stimulated gene ISG-15 in the interferon-	
			omega-mediated inhibition of human immunodeficiency virus replication. J	
			Interferon Cytokine Res 1996;16:919-27	
		D35	LEE JH, et al., Dynamics of hepatitis C virus quasispecies turnover during	
		555	interferon-A treatment. Program and abstracts of Digestive Disease Week 2000;	
			May 21-24, 2000; San Diego, California. Abstract 974.	
		D26	LUKASZEWSKI RA et al., Pegylated alpha interferon is an effective treatment	
		D36		
			for virulent Venezuelan equine encephalitis virus and has profound effects on the	
	<u> </u>		host immune response to infection. J Virol 2000 Jun;74(11):5006-15	
		D37	MCHUTCHISON JG, et al., Interferon alfa-2b alone or in combination with	
			ribavirin as initial treatment for chronic hepatitis C. N Engl J Med.	
	<b></b>	ļ	1998;339:1485-1492.	
		D38	MERAD M et al., Generation of monocyte-derived dendritic cells from patients	
			with renal cell cancer: modulation of their functional properties after therapy with	
	1		biological response modifiers (IFN-alpha plus IL-2 and IL-12). J Immunother	
			2000 May-Jun;23(3):369-78	
		D39	MILELLA M, et al., Neutralizing antibodies to recombinant alpha-interferon and	
			response to therapy in chronic hepatitis C infection. Liver 1993; 13 (3):146-150	
		D40	NEUMANN A, et al., Hepatitis C viral dynamics in vivo and the antiviral	
6.0			efficacy of interferon-alpha therapy. Science 282;1998:103-7	
		D4:	NIEFORTH KA et al., Use of an indirect pharmacodynamic stimulation model of	
		D41		
			MX protein induction to compare in vivo activity of interferon alfa-2a and a	
			polyethylene glycol-modified derivative in healthy subjects. : Clin Pharmacol	
	-		Ther 1996 Jun;59(6):63646	
	\	D42	OLASO V et al., Early prediction of lack of response to treatment with interferon	
			and interferon plus ribavirin using biochemical and virological criteria in patients	
	L &		with chronic hepatitis C; Esp Quimioter; 1999 Sep;12(3):220-8	

PANITCH HS, Interferons in multiple sclerosis. Drugs 1992; 44 (6): 946-962  PIMSTONE NR, et al., High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C. Program and abstracts of Digestive Disease Week 2000; May 21-24, 2000; San Diego, California. Abstract 973.  POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. Hepatology 2000; 31:211-218.  POYNARD T, et al., Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.  DAY QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al., eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  DAS SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  DAY SHIFFMAN ML, et al.; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histological miprovement in hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  DSS HIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  DSS IMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon—2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  DSS TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepat				
is highly effective treatment for hepatitis C. Program and abstracts of Digestive Disease Week 2000; May 21-24, 2000; San Diego, California. Abstract 973.  POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. POYNARD T, et al., Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks of for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.  D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 2;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of		D43	PANITCH HS, Interferons in multiple sclerosis. Drugs 1992; 44 (6): 946-962	
is highly effective treatment for hepatitis C. Program and abstracts of Digestive Disease Week 2000; May 21-24, 2000; San Diego, California. Abstract 973.  POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. POYNARD T, et al., Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks of for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.  D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 2;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of	134			
is highly effective treatment for hepatitis C. Program and abstracts of Digestive Disease Week 2000; May 21-24, 2000; San Diego, California. Abstract 973.  POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. POYNARD T, et al., Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks of for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.  D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 2;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of	100	D44	PIMSTONE NR, et al., High dose (780 MIU/52 weeks) interferon monotherapy	
POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. Hepatology 2000;31:211-218.    D46	١١			H
POYNARD T, et al., Is an "a la carte" combined interferon alfa 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C. Hepatology 2000;31:211-218.    D46	1		, ,	오
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce		D45		<u> </u>
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce	لم ا	1		2
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce	PILE	120		豆
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce	$\vdash$	ļ '		<u> </u>
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce	0 0 20			8
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce	hor a also			8
D47 QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain absce		5		8
MALIGNANCIES: Non-serial; The Interferon System. A Current Review to 1987. Baron S et al., eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med In	Pe muses	ME	1432.	0
1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- COLANGE	D47	QUESADA JR et al., INTERFERONS IN HEMATOLOGICAL	
1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			MALIGNANCIES: Non-serial; The Interferon System. A Current Review to	
Biomedical Science, Austin, TX, University of Texas Press, p. 487-95, 1987  SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  BHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  Bimma T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
D48 SEN GC et al., The interferon system. J. Biol. Chem. 1992; 267: 5017-5020.  D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
D49 SHIFFMAN ML, et al.,; A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	<del>-  </del>	DAS		
interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-\alpha-22 (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	1	240	521, 55 of al., The interferon system. J. Dioi. Chem. 1772, 207. 5017-5020.	
interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-\alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	. 1			
interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D49	SHIFFMAN ML, et al; A decline in HCV-RNA level during interferon or	
with an improvement in hepatic histology. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			•	
Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- 1			
Study of Liver Diseases; November 5-9, 1999; Dallas, Texas. Abstract 567.  D50 SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- 1		<u> </u>	
SHIMA T et al., Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- 1		· ·	
histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9  D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- 1	D50	· • • • • • • • • • • • • • • • • • • •	
<ul> <li>D51 SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92</li> <li>D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109</li> <li>D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9</li> <li>D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667</li> <li>D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645</li> <li>D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7</li> </ul>				
MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative Research Group.: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			treatment. J. Gastroenterol Hepatol 2000 Mar; 15(3):294-9	
Research Group: Munschauer FE 3rd Neurology 2000 Jul 25;55(2):185-92  D52 SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D51	SIMON JH et al., A longitudinal study of T1 hypointense lesions in relapsing	
SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	- 1		MS: MSCRG trial of interferon betala. Multiple Sclerosis Collaborative	
SULKOWSKI M. et al., Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
chronic hepatitis C: a phase II open label study. Biodrugs 2002:16(2)105-109  D53 TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D52		
TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			omone hepaticis of a phase in open label study. Diodiugs 2002.10(2)103-109	
carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  D54 THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  D55 TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D53	TANAKA H et al., Effect of interferon therapy on the incidence of hepatocellular	
cohort study of 738 patients. Int J Cancer 2000 Sep 1;87(5):741-9  THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			•••	
THE IFNB MULTIPLE SCLEROSIS STUDY GROUP; Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	1			
effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655-667  TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D54		
TONG MJ et al., Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			circuit o in relapsing-remitting multiple scierosis. Treutology 1979, 43. 055-00/	
chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		D55	TONG MJ et al., Prediction of response during interferon alfa 2b therapy in	
comparison. Hepatology 1997; 26 (6):1640-1645  D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7				
D56 TOUZA REY F et al., The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7	119			
with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7			10mpm.com 110pm.ciogj 1557, 20 (0).1070-1075	
with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus An Med Interna 2000 Feb; 17(2):86-7		Dec	TOUZA DEV E et al. The elipical regresses to interferen comme in the	
fumigatus An Med Interna 2000 Feb; 17(2):86-7		D56		
D57   WEINSTOCK-GUTTMAN B et al., What is new in the treatment of multiple				
	,	D57		
sclerosis?; Drugs 2000 Mar;59(3):401-10	W		sclerosis?; Drugs 2000 Mar;59(3):401-10	
		لـــيــا		

	1	D58	WEISSMANN C, et al., The interferon genes. Prog. Nucleic Acid Res. 1986; 33: 251-300		
7		D59	WRIGHT HI et al., Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992 Jan;53(l):121-4		
		D60	YOUNOSSI ZM et al., The roles of amantadine, rimantadine, ursodeoxycholic		1
	<b>DI</b>	(he)	acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C Semin Liver Dis 1999;19 Suppl 1:95-102		L
PATENTE	U 0 g	D61 2002	Ther 1998 Dec;4(4):229-41	T TNF	T ( )
N. C.	RADEN	DARRE	ZEUZEM S, et al., Hepatitis C Virus Dynamics In Vivo: Effect of Ribavirin and Interferon Alfa on Viral Turnover. Hepatology 1998;28:245-52.	5 2002	
a		D63	ZIESCHE R et al., A Preliminary Study of Long-Term Treatment with Interferom Gamma-1b and Low-Dose Prednisolone in Patients with Idopathic Pulmonary Fibrosis New Engl J Med 1999; 341:1264-9.		Ė

Examiner Signature	11. 18 Chs	Date Considered	6.11.03
*EXAMINER:	Initial if reference considered, whether or not cit	tation is in conformance with I	MPEP 609. Draw line through citation if not in conformance
and not conside	red. Include copy of this form with next commun	dication to applicant.	

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.

/o`.' ~	6						PTO/SB/08A (08-00)
SE 30 T		bstitute for form 1	449A/PT	0		Complete if Kn	own
48 3°	1 1				Application Number	10/004,118	DEOENTER
	1 . 711			SCLOSURE	Filing Date	October 30, 2001	RECEIVED
TRATE B TRATE	<b>√</b> S	TATEMENT	EMENT BY APPLICANT		First Named Inventor	Moran	
TRAU	7	,			Group Art Unit	1644	SEP 0 3 2002
		(use as many :	sheets a.	s necessary)	Examiner Name		- 0C1 0 C00C
	Sheet	1	of	1	Attorney Docket Number	BMED-004/01US	TECH CENTER 1600/200
							THE PERSON NAMED OF THE PE

			U.S. P	ATENT DOCUMENTS	
		U.S. Patent	Document		D. CD.III ii GG
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
6/1	P2	4,673,405		Guittard et al.	06-16-1987
7 1	P3	5,908,621		Glue et al.	06-01-1999
1					

•				FOREIGN PA	ATENT DOCUMENTS		
Examiner Initials*	Cite No.1	F	oreign Patent Doc	ument		Date of Publication	
mittais	140.	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	T⁴
	-						

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т					
Mh	D64	ZEIDNER et al., Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2', 3'-dideoxycytidine, Antiviral Research, 11 (1989) 147-160						
Ý		·						

Examiner		n	Date		
Signature	1./1/	-11s	Considered	6.11.03	
ACMANDED		V			

\*EXAMINER: Integral if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered/Include copy of this form with next communication to applicant.

Unique citation designation number.

<sup>&</sup>lt;sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>&</sup>lt;sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>&</sup>lt;sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>&</sup>lt;sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.